Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?

• The prevalence of aPL antibodies is poorly documented in ICU COVID-19 patients. • LA based on dRVVT system was positive in 85% of critically ill COVID-19 patients. • LA was not associated with thrombotic complications. • The prevalence of elevated anticardiolipin IgG/M/anti-beta2-GPI IgG was of 12...

Descripción completa

Detalles Bibliográficos
Autores principales: Siguret, Virginie, Voicu, Sebastian, Neuwirth, Marie, Delrue, Maxime, Gayat, Etienne, Stépanian, Alain, Mégarbane, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Letter to the Editors-in-Chief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342042/
https://www.ncbi.nlm.nih.gov/pubmed/32663703
http://dx.doi.org/10.1016/j.thromres.2020.07.016
Descripción
Sumario:• The prevalence of aPL antibodies is poorly documented in ICU COVID-19 patients. • LA based on dRVVT system was positive in 85% of critically ill COVID-19 patients. • LA was not associated with thrombotic complications. • The prevalence of elevated anticardiolipin IgG/M/anti-beta2-GPI IgG was of 12%.

Ejemplares similares